LRRK2 Cohort Consortium

The LRRK2 Cohort Consortium (LCC) was created to assemble and study groups of people with and without Parkinson’s disease who carry mutations in the LRRK2 gene. It comprises three closed studies: the LRRK2 Cross-sectional Study, LRRK2 Longitudinal Study and the 23andMe Blood Collection Study. The LCC followed standardized data acquisition protocols, and clinical data and biological samples are stored in a comprehensive Parkinson’s database and biorepository, respectively. 

LRRK2 Cross-sectional Study
Study Subjects:

• 797 idiopathic PD; 508 controls
• 823 LRRK2+ PD patients (mainly G2019S); 722 LRRK2+ carriers without PD (mainly G2019S)

Available Data:

• Clinical: motor, non-motor (cognitive, neurobehavioral, neuropsychological, autonomic, sleep)
• Imaging: fMRI, DaTSCAN SPECT, FDG PET, transcranial ultrasound (calculated data only; raw images not available)
• Genetic: Whole genome sequencing

LRRK2 Longitudinal Study
Study Subjects: 

• 94 idiopathic PD patients, 84 controls
• 97 LRRK2+ PD patients (G2019S), 86 LRRK2+ carriers without PD (G2019S)

Available Data:

• Clinical: motor, non-motor (cognitive, neurobehavioral, neuropsychological, autonomic, sleep)
• Imaging: fMRI, DaTSCAN SPECT, FDG PET, transcranial ultrasound (calculated data only; raw images not available)
• Genetic: Whole genome sequencing

23andMe Blood Collection Study
Study Subjects: 

• 31 idiopathic PD patients, 31 controls
• 63 LRRK2+ PD patients (mainly G2019S), 227 LRRK2+ carriers without PD (mainly G2019S)

Available Data:

• Demographics, limited family history
• Limited UPDRS, UPSIT
• Limited information on anti-inflammatory medications and head injury or concussion
• Whole genome sequencing

• Data Use Agreement
• Publications Policy
• Case Report Form
• LCC Investigators